Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,324 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
How Tlg2p/syntaxin 16 'snares' Vps45.
Dulubova I, Yamaguchi T, Gao Y, Min SW, Huryeva I, Südhof TC, Rizo J. Dulubova I, et al. Among authors: yamaguchi t. EMBO J. 2002 Jul 15;21(14):3620-31. doi: 10.1093/emboj/cdf381. EMBO J. 2002. PMID: 12110575 Free PMC article.
Nurse-Led Screening-Triggered Early Specialized Palliative Care Program for Patients With Advanced Lung Cancer: A Multicenter Randomized Controlled Trial.
Matsumoto Y, Umemura S, Okizaki A, Fujisawa D, Yamaguchi T, Oyamada S, Miyaji T, Mashiko T, Kobayashi N, Satomi E, Kiuchi D, Morita T, Uchitomi Y, Goto K, Ohe Y. Matsumoto Y, et al. Among authors: yamaguchi t. Cancer Med. 2024 Nov;13(22):e70325. doi: 10.1002/cam4.70325. Cancer Med. 2024. PMID: 39556485 Clinical Trial.
StableLift: Optimized Germline and Somatic Variant Detection Across Genome Builds.
Wang NK, Wiltsie N, Winata HK, Fitz-Gibbon S, Gonzalez AE, Zeltser N, Agrawal R, Oh J, Arbet J, Patel Y, Yamaguchi TN, Boutros PC. Wang NK, et al. Among authors: yamaguchi tn. bioRxiv [Preprint]. 2024 Nov 3:2024.10.31.621401. doi: 10.1101/2024.10.31.621401. bioRxiv. 2024. PMID: 39554127 Free PMC article. Preprint.
A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly emetogenic chemotherapy in breast cancer (PATROL-II).
Suzuki K, Yokokawa T, Kawaguchi T, Takada S, Tamaki S, Kawasaki Y, Yamaguchi T, Koizumi K, Matsumoto T, Sakata Y, Arakawa Y, Ayuhara H, Hosonaga M, Yamaguchi M, Tsuji D. Suzuki K, et al. Among authors: yamaguchi t. Sci Rep. 2024 Nov 16;14(1):28271. doi: 10.1038/s41598-024-79781-6. Sci Rep. 2024. PMID: 39550497 Free PMC article. Clinical Trial.
9,324 results